Dry Eye Profiles in Patients with a Positive Elevated Surface Matrix Metalloproteinase 9 Point-of-Care Test Versus Negative Patients

Nicole L. Lanza, Allison L. McClellan, Hatim Batawi, Elizabeth Felix, Konstantinos D. Sarantopoulos, Roy C Levitt, Anat Galor

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Purpose To compare dry eye (DE) symptoms and signs in subjects who tested positive versus those who tested negative for ocular surface matrix metalloproteinase 9 (MMP-9) using the InflammaDry point-of-care test (RPS, Sarasota, FL). Methods In this cross-sectional study, individuals seen in the Miami Veterans Affairs eye clinic with DE symptoms, as evidenced by DE questionnaire 5 (DEQ5) ≥6, were given standardized questionnaires to assess DE symptoms and ocular and non-ocular pain complaints. Also, a complete evaluation was conducted to measure ocular surface signs of DE. MMP-9 testing was performed using the InflammaDry once in each eye, per the manufacturer's instructions. The main outcome measure was a comparison of DE symptoms and signs in MMP-9 positive versus negative subjects. Results Of 128 subjects, 50 (39%) were positive for MMP-9 for InflammaDry testing in either eye. No statistically significant differences in mental health indices, DE symptoms, or ocular surface signs were seen in subjects based on MMP-9 status. Conclusion In our population, there was no difference in the DE profile by both symptoms and signs between those testing positive versus negative for MMP-9 on the ocular surface. This suggests that clinical exam alone cannot predict patients with clinically significant inflammation.

Original languageEnglish (US)
Pages (from-to)216-223
Number of pages8
JournalOcular Surface
Volume14
Issue number2
DOIs
StatePublished - Apr 1 2016

Fingerprint

Point-of-Care Systems
Matrix Metalloproteinase 9
Signs and Symptoms

Keywords

  • dry eye
  • InflammaDry
  • matrix metalloproteinase-9

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Dry Eye Profiles in Patients with a Positive Elevated Surface Matrix Metalloproteinase 9 Point-of-Care Test Versus Negative Patients. / Lanza, Nicole L.; McClellan, Allison L.; Batawi, Hatim; Felix, Elizabeth; Sarantopoulos, Konstantinos D.; Levitt, Roy C; Galor, Anat.

In: Ocular Surface, Vol. 14, No. 2, 01.04.2016, p. 216-223.

Research output: Contribution to journalArticle

@article{2fbad53e85104071b4c0561eb5e3d632,
title = "Dry Eye Profiles in Patients with a Positive Elevated Surface Matrix Metalloproteinase 9 Point-of-Care Test Versus Negative Patients",
abstract = "Purpose To compare dry eye (DE) symptoms and signs in subjects who tested positive versus those who tested negative for ocular surface matrix metalloproteinase 9 (MMP-9) using the InflammaDry point-of-care test (RPS, Sarasota, FL). Methods In this cross-sectional study, individuals seen in the Miami Veterans Affairs eye clinic with DE symptoms, as evidenced by DE questionnaire 5 (DEQ5) ≥6, were given standardized questionnaires to assess DE symptoms and ocular and non-ocular pain complaints. Also, a complete evaluation was conducted to measure ocular surface signs of DE. MMP-9 testing was performed using the InflammaDry once in each eye, per the manufacturer's instructions. The main outcome measure was a comparison of DE symptoms and signs in MMP-9 positive versus negative subjects. Results Of 128 subjects, 50 (39{\%}) were positive for MMP-9 for InflammaDry testing in either eye. No statistically significant differences in mental health indices, DE symptoms, or ocular surface signs were seen in subjects based on MMP-9 status. Conclusion In our population, there was no difference in the DE profile by both symptoms and signs between those testing positive versus negative for MMP-9 on the ocular surface. This suggests that clinical exam alone cannot predict patients with clinically significant inflammation.",
keywords = "dry eye, InflammaDry, matrix metalloproteinase-9",
author = "Lanza, {Nicole L.} and McClellan, {Allison L.} and Hatim Batawi and Elizabeth Felix and Sarantopoulos, {Konstantinos D.} and Levitt, {Roy C} and Anat Galor",
year = "2016",
month = "4",
day = "1",
doi = "10.1016/j.jtos.2015.12.007",
language = "English (US)",
volume = "14",
pages = "216--223",
journal = "Ocular Surface",
issn = "1542-0124",
publisher = "Ethis Communications, Inc.",
number = "2",

}

TY - JOUR

T1 - Dry Eye Profiles in Patients with a Positive Elevated Surface Matrix Metalloproteinase 9 Point-of-Care Test Versus Negative Patients

AU - Lanza, Nicole L.

AU - McClellan, Allison L.

AU - Batawi, Hatim

AU - Felix, Elizabeth

AU - Sarantopoulos, Konstantinos D.

AU - Levitt, Roy C

AU - Galor, Anat

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Purpose To compare dry eye (DE) symptoms and signs in subjects who tested positive versus those who tested negative for ocular surface matrix metalloproteinase 9 (MMP-9) using the InflammaDry point-of-care test (RPS, Sarasota, FL). Methods In this cross-sectional study, individuals seen in the Miami Veterans Affairs eye clinic with DE symptoms, as evidenced by DE questionnaire 5 (DEQ5) ≥6, were given standardized questionnaires to assess DE symptoms and ocular and non-ocular pain complaints. Also, a complete evaluation was conducted to measure ocular surface signs of DE. MMP-9 testing was performed using the InflammaDry once in each eye, per the manufacturer's instructions. The main outcome measure was a comparison of DE symptoms and signs in MMP-9 positive versus negative subjects. Results Of 128 subjects, 50 (39%) were positive for MMP-9 for InflammaDry testing in either eye. No statistically significant differences in mental health indices, DE symptoms, or ocular surface signs were seen in subjects based on MMP-9 status. Conclusion In our population, there was no difference in the DE profile by both symptoms and signs between those testing positive versus negative for MMP-9 on the ocular surface. This suggests that clinical exam alone cannot predict patients with clinically significant inflammation.

AB - Purpose To compare dry eye (DE) symptoms and signs in subjects who tested positive versus those who tested negative for ocular surface matrix metalloproteinase 9 (MMP-9) using the InflammaDry point-of-care test (RPS, Sarasota, FL). Methods In this cross-sectional study, individuals seen in the Miami Veterans Affairs eye clinic with DE symptoms, as evidenced by DE questionnaire 5 (DEQ5) ≥6, were given standardized questionnaires to assess DE symptoms and ocular and non-ocular pain complaints. Also, a complete evaluation was conducted to measure ocular surface signs of DE. MMP-9 testing was performed using the InflammaDry once in each eye, per the manufacturer's instructions. The main outcome measure was a comparison of DE symptoms and signs in MMP-9 positive versus negative subjects. Results Of 128 subjects, 50 (39%) were positive for MMP-9 for InflammaDry testing in either eye. No statistically significant differences in mental health indices, DE symptoms, or ocular surface signs were seen in subjects based on MMP-9 status. Conclusion In our population, there was no difference in the DE profile by both symptoms and signs between those testing positive versus negative for MMP-9 on the ocular surface. This suggests that clinical exam alone cannot predict patients with clinically significant inflammation.

KW - dry eye

KW - InflammaDry

KW - matrix metalloproteinase-9

UR - http://www.scopus.com/inward/record.url?scp=84963957464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963957464&partnerID=8YFLogxK

U2 - 10.1016/j.jtos.2015.12.007

DO - 10.1016/j.jtos.2015.12.007

M3 - Article

C2 - 26807724

AN - SCOPUS:84963957464

VL - 14

SP - 216

EP - 223

JO - Ocular Surface

JF - Ocular Surface

SN - 1542-0124

IS - 2

ER -